Clinical trials
5 active studies led by Cartesian Therapeutics, of 12 in all
Source: ClinicalTrials.gov, Studies with Cartesian Therapeutics (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 2Markets in public records
- 0Regions & countries
- 5Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Cartesian Therapeutics or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Cartesian Therapeutics
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Stock listing
- NASDAQ: RNAC
- Type
- Medicines
Source: SEC EDGAR, Company filings, CIK 1453687. Retrieved 13 Nov 2026.
See them on ClinicalTrials.gov (opens in a new tab)
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1453687.
Trials over time
Studies Cartesian Therapeutics leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Cartesian Therapeutics or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Cartesian Therapeutics: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Cartesian Therapeutics is in.
From our blog
Stories on the topics Cartesian Therapeutics works in.
Brain Cancer Diagnosis: Imaging and New Biomarkers
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Alzheimer's Diagnosis: Blood Tests and Earlier Answers
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read
Cannabis-Based Medicines: Science and Regulation
The FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
Read